早发性卵巢功能不全 中国就医指南

Premature Ovarian Insufficiency (POI) is a clinical syndrome characterized by the loss of ovarian function before age 40, marked by amenorrhea (absence of menstruation for ≥4 months), elevated follicle-stimulating hormone (FSH) levels (>25 IU/L on two occasions >4 weeks apart), and estrogen deficiency. Unlike natural menopause, POI is not always permanent—approximately 5–10% of affected individuals experience intermittent ovarian activity and even spontaneous pregnancy. The pathogenesis is heterogeneous and multifactorial: genetic causes (e.g., X-chromosome abnormalities like Turner syndrome, FMR1 premutation, BMP15, FOXL2 mutations), autoimmune disorders (e.g., associated with thyroiditis, Addison’s disease, or type 1 diabetes), iatrogenic factors (chemotherapy, pelvic radiotherapy, or ovarian surgery), metabolic conditions (galactosemia), and environmental toxins may all contribute. In up to 90% of cases, however, no definitive cause is identified—termed idiopathic POI. Epidemiologically, POI affects approximately 1% of women under age 40 and 0.1% under age 30. Incidence rises slightly in populations with consanguinity or known familial clustering. Key risk factors include family history of early menopause, prior gonadotoxic treatment, autoimmune disease, chromosomal anomalies, and certain infections (e.g., mumps oophoritis, though rare). Beyond reproductive implications—including infertility, which affects nearly all patients—POI significantly impacts long-term health and quality of life. Estrogen deficiency accelerates bone mineral density loss (increasing osteoporosis and fracture risk), elevates cardiovascular disease risk, and contributes to vasomotor symptoms (hot flashes, night sweats), sleep disturbances, vaginal atrophy, decreased libido, and mood disorders such as anxiety and depression. Cognitive concerns—including reduced verbal memory and executive function—have also been reported. Psychosocial burden is profound: diagnosis often coincides with identity formation and family-building years, triggering grief, diminished self-esteem, relationship strain, and social isolation. Early multidisciplinary care—including endocrinology, reproductive medicine, mental health support, and bone/cardiovascular risk assessment—is essential. Hormone replacement therapy (HRT) remains the cornerstone of management to alleviate symptoms and mitigate long-term sequelae, while fertility preservation counseling (e.g., egg donation, embryo adoption, surrogacy) must be offered sensitively and promptly. Lifestyle interventions—weight-bearing exercise, calcium/vitamin D supplementation, smoking cessation, and cardiovascular risk monitoring—are integral components of holistic care.

# 早发性卵巢功能不全（POI）治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

• •激素替代治疗（HRT）：适用于无禁忌证、有雌激素缺乏症状或骨密度下降者。

- 高阶方案（经皮雌二醇贴剂+地屈孕酮）：年费用约 12,000–22,000元（含个体化监测、AMH、FSH动态评估）。

• •DHEA辅助治疗：仅限AMH＜0.5 ng/mL且尝试自然妊娠者，年费用约 4,800–9,600元（含血清DHEA-S检测及肝肾功能随访）。

二、手术/介入方案

POI为内分泌功能衰竭，无根治性手术指征；生殖医学科不开展卵巢相关切除或重建术。仅对合并子宫内膜病变、卵巢囊肿等需干预者，按妇科常规处理（如宫腔镜诊刮、腹腔镜囊肿剔除），费用另计。

三、特殊复杂情况方案

• •合并自身免疫性甲状腺炎/肾上腺抗体阳性：加用小剂量糖皮质激素+免疫调节随访，年增检查及药费 2,400–6,000元；
• •反复IVF失败（≥3次）伴严重卵巢低反应：可考虑卵子捐赠助孕，全流程费用 120,000–180,000元（含供卵匹配、胚胎移植、黄体支持及妊娠监护）。

四、方案快速选择指南

• •预算有限/初诊患者：首选基础HRT（3,600元/年）；
• •有生育需求且AMH＞0.2 ng/mL：HRT联合促排卵监测（年总费用约10,000元）；
• •已确诊耐药或高龄（＞38岁）：直接评估供卵助孕可行性。